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erated in patients who are PCR-positive at the time of transplan-
tation. Reinfection signiﬁcantly impairs patient and graft survival
[1]. At present, there are limited options available to prevent graft
reinfection after transplantation or to successfully treat rein-
fected patients. Pretransplant antiviral combination therapy with
(peg)interferon/ribavirin (PegIFN/RBV) is poorly tolerated and
not very effective in patients infected with HCV genotype 1. In
a prospective randomized controlled study, pretransplant treat-
ment with PegIFN/RBV prevented post-transplant recurrence of
HCV in 22% of a highly selected group of patients with HCV geno-
types 1,4,6 [2]. Treatment after transplantation has also a limited
efﬁcacy and is associated with serious adverse effects. Currently,
studies using triple therapy with PegIFN/RBV and a protease
inhibitor (boceprevir or telaprevir) are ongoing, but again poor
tolerance is a major issue.
Thus there is urgent medical need to develop safe and effec-
tive treatments for this group of patients. Two case reports indi-
cated that therapy with intravenous silibinin (iv-SIL; Legalon
SIL, Rottapharm–Madaus) successfully eradicated the virus after
transplantation [3,4]. Based on these encouraging observations, iv
silibinin got EMA orphan drug designation for prevention of
recurrent hepatitis C. Iv-SIL is a 1:1 mixture of silibinin A and sil-
ibinin B and is available as intravenous therapeutic agent for
treatment of mushroom poisoning. However, acute liver failure
related to mushroom (amanita or lepiota) poisoning is an uncom-
mon condition and there is no deﬁnitive evidence that silibinin
improves the outcome of these patients.
In 2008, the potent antiviral activity of iv-SIL against HCV was
described [5] and conﬁrmed by in vitro studies [6]. Silibinin inhib-
its the HCV NS5B polymerase activity directly [7] or by interfering
with the binding of the RNA to this enzyme [8]. Furthermore, the
mechanisms of the antiviral action of silibinin appear also toJournal of Hepatology 20
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Open access under CC BY-NC-ND license.include blocking of virus entry, transmission, and secretion (for
review see [9]).
In this issue of the Journal, 2 groups from Spain report their
experience with iv-SIL in the transplant setting [10,11]. Both
studies involved only a very small number of patients, but both
included a control group: in the study performed in Madrid this
was a historical control [10], while in the one performed in Bar-
celona, patients in the control group were treated with a placebo
according to a prospective randomized, double-blind, placebo-
controlled design [11].The Madrid group [10] started iv-SIL dur-
ing the anhepatic phase and continued treatment for 21 days.
In contrast, the Barcelona group [11] treated patients for up to
21 days prior transplantation, and continued or restarted the
infusion for further 7 days after transplantation. Both studies
conﬁrmed the robust antiviral efﬁcacy and the safety of iv silibi-
nin in this difﬁcult-to-treat patients, with the apparent lack of
interaction with immunosuppressants, but not surprisingly, both
approaches failed to eradicate the virus in a single patient,
although quite a few had undetectable HCV RNA at the end of
iv silibinin administration.
It is quite clear that giving an antiviral drug as monotherapy
for just 21 days is not able to eradicate HCV. The so far shortest
successful treatment in HCV genotype 1 patients having the
IL28B CC genotype using peginterferon/ribavirin and telaprevir
was 12 weeks [12]. Comparison with other published reports of
iv silibinin (Table 1) shows that the best results in terms of SVR
were obtained in patients in whom a low viral load was achieved
by administering the drug before transplant and then continuing
it for 3–4 weeks after transplant [4]. Taken together, the data
published so far seem to indicate that HCV RNA levels below
the level of quantiﬁcation (LOQ) at the end of iv silibinin admin-
istration and SVR can be reached in 12/14 (85.7%) and 3/14
(21.4%) patients with a continuous pre-/post-transplant adminis-
tration, respectively, while in patients receiving iv silibinin only
after transplant, the same results could be achieved only in 6/
35 (17.1%) and 2/35 (5.7%) patients, respectively (Table 1).
Studies in the transplant setting are difﬁcult to design. The
problems even increase if patients immediately prior to trans-
plantation are involved. They are usually very sick and safety
becomes the prime issue. Pretreating patients with iv-SIL is feasi-
ble and safe, but is limited by the need of daily infusions. The opti-
mal timing for transplantation would be if the patient becomes
HCV RNA undetectable, but the timing of transplantation depends13 vol. 58 j 409–411
Table 1. Cases treated with intravenous silibinin in the transplant setting.
Author, [Ref.] Continuous pre/post-LTX Pre-LTX and later post-LTX Post-LTX Pre-LTX only
n HCV <LOQ 
at end of iv-SIL
SVR n HCV <LOQ 
at end of iv-SIL
SVR n HCV <LOQ 
at end of iv-SIL
SVR n HCV <LOQ 
at end of iv-SIL
SVR
[10] 9 4 0
Mariño et al., [11] 4 4 0 4 1 0 3 1&,§ 0
Eurich et al., [16] 4 1
Beinhardt et al., [13] 10 8 3*,# 6 0 0 4 2§ 1
Neumann et al., [3] 1 1
1
1
Aghemo et al., [17] 1 0 0
Rendina$ et al., [18] 14 0 0
Total 14 12 3 4 1 0 35 6 2 7 3 1
Bárcena et al.,
iv-SIL, intravenous silibinin (20 mg/kg body weight/day); <LOQ = <15 IU/ml.
⁄Includes the case reported [4].
#One patient died 3 months after transplantation, she was HCV RNA negative.
§One patient died on the waiting list.
$Treated >1 year after LTX. (See above mentioned references for further information.)
&2 not transplanted.
Editorialon the availability of a donor organ, which is increasingly chal-
lenging in an era of donor organ shortage. Therefore, in some
patients, infusion therapy had to be stopped before transplanta-
tion was performed.
In the Barcelona study, this was the case in 4 patients. Iv sil-
ibinin was restarted 7 to 38 days after the 21 days of silibinin
administration. HCV below the level of quantiﬁcation (LOQ)
was achieved only in 1 of 4 of them in contrast to all of the 4
patients treated continuously. Similarly, in 3 patients treated pre-
transplant in our center, no liver was available when the targeted
low or undetectable viral load was reached (updated from [13]).
One patient even subsequently achieved SVR but died on the
waiting list. Obviously the best approach would be to do the
study at centers offering living donor transplantation. In such
centers, treatment and transplantation can be scheduled exactly.
A very important aspect in such a study would be to investigate
the needed duration of silibinin monotherapy and/or the need for
consecutive treatment with peginterferon/ribavirin, possibly in
combination with a direct acting antiviral agent. It is conceivable
that the optimization of the duration of treatment with iv-SIL,
even after cadaveric donor transplantation (e.g., for at least
4 weeks) and/or combination therapy could improve the virolog-
ical response by reducing viral load in the ﬁrst weeks after trans-
plantation. This may prevent, delay, or decrease the severity of
recurrent hepatitis C, with favourable histological ﬁndings at 6–
12 months [14]. This would represent per se a clinically relevant
outcome.
So what do we learn from these studies? Iv-SIL is safe but by
the currently used applications cannot prevent graft reinfection
or eradicate HCV from the transplanted liver in most patients.
At present there is no alternative of an interferon-free approach
in the peritransplant setting and silibinin may be the ideal drug
until safe and effective HCV RNA polymerase inhibitors with a high
genetic barrier become available. Nevertheless, there is a need for
improvements in treatment schedules before such a treatment
can be recommended. Flushing the liver graft with a solution
containing silibinin as it has been done to prevent oxidative dam-410 Journal of Hepatology 201age to the liver [15] should be tested in order to determine if it
helps prevent recurrence.Conﬂict of interest
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